The surgery was part of a clinical study to evaluate the effectiveness of a device that combines two cardiac therapies: Cardiac contractility modulation, which improves the contraction of the heart, and an implantable cardioverter defibrillator, which treats arrhythmias that cause sudden cardiac death.
“This could be an important advancement for heart failure patients, requiring just one procedure to deliver two important therapies and prevent sudden cardiac death,” Bruce Wilkoff, MD, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic and principal investigator for the INTEGRA-D study, said in a May 18 system news release. “The hope is that this rechargeable technology — with a potential battery life of up to 20 years — will significantly reduce the need for replacement procedures.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
